Cole D R, Pung J
Antimicrob Agents Chemother. 1977 Jun;11(6):1033-5. doi: 10.1128/AAC.11.6.1033.
Single doses of cefazolin, 500 mg intramuscularly and 1 g intravenously, were administered to 16 patients having lung pathology who were scheduled for thoracic fluid aspiration. Pleural fluid and serum samples were taken at intervals of 30 to 240 min for determination of cefazolin levels. The levels obtained were variable; however, the levels of cefazolin in pleural fluid generally exceeded the reported minimal inhibitory concentration values for Staphylococcus pneumoniae and Staphylococcus, and group A beta-hemolytic streptococcus. In addition, the pleural fluid levels exceeded the minimal inhibitory concentration for cefazolin against most of the Klebsiella and Haemophilus influenzae strains. These data show that cefazolin, despite its comparative high protein binding, produces levels in the pleural fluid capable of inhibiting the organisms commonly found in respiratory tract infections.
对16例计划进行胸腔积液抽吸且患有肺部疾病的患者,分别肌内注射500mg头孢唑林单剂量和静脉注射1g头孢唑林单剂量。每隔30至240分钟采集胸膜液和血清样本,以测定头孢唑林水平。所获得的水平各不相同;然而,胸膜液中头孢唑林的水平通常超过了报道的肺炎链球菌、葡萄球菌和A组β溶血性链球菌的最低抑菌浓度值。此外,胸膜液水平超过了头孢唑林对大多数克雷伯菌和流感嗜血杆菌菌株的最低抑菌浓度。这些数据表明,头孢唑林尽管其蛋白结合率相对较高,但在胸膜液中产生的水平能够抑制呼吸道感染中常见的微生物。